Zwitterionic polymer with minimal reactivity against PEG antibodies to enhance the therapeutic effects of cytokine-targeting DNA aptamer. (Record no. 62079)

MARC details
000 -LEADER
fixed length control field 02369nam a2200289Ia 4500
003 - CONTROL NUMBER IDENTIFIER
control field MX-MdCICY
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20251009160712.0
040 ## - CATALOGING SOURCE
Transcribing agency CICY
090 ## - LOCALLY ASSIGNED LC-TYPE CALL NUMBER (OCLC); LOCAL CALL NUMBER (RLIN)
Classification number (OCLC) (R) ; Classification number, CALL (RLIN) (NR) B-21991
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 251009s9999 xx 000 0 und d
245 10 - TITLE STATEMENT
Title Zwitterionic polymer with minimal reactivity against PEG antibodies to enhance the therapeutic effects of cytokine-targeting DNA aptamer.
490 0# - SERIES STATEMENT
Series statement Biomaterials Science, 13(5), 1347-1353, 2025.
500 ## - GENERAL NOTE
General note Artículo
520 3# - SUMMARY, ETC.
Summary, etc. Overcoming poor in vivo pharmacokinetics is a critical challenge in developing therapeutic aptamers, and conjugation to poly(ethylene glycol) (PEG) is a well-established technique for aptamers to prolong blood circulation. However, the existence of antibodies that specifically recognize PEG and their adverse effects on in vivo behaviors have been increasingly reported, highlighting the necessity of alternative modification strategies for aptamers. To address this issue, we focused on a zwitterionic polymer, particularly poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC), as a PEG alternative to modify DNA aptamers. We conjugated PMPC to a DNA aptamer targeting IFN-gamma and investigated the properties of the PMPC-conjugated DNA aptamer as a therapeutic agent. PMPC modification did not affect the neutralizing activity of the aptamer. PMPC demonstrated lower reactivity against anti-PEG antibodies than PEG-like aptamer modifiers previously reported to exhibit low reactivity against PEG antibodies. In addition, PMPC extended the blood circulation time of the aptamer as long as or longer than PEG with a similar molecular size. In the LPS-induced inflammation animal model, the survival rate after treatment with the PMPC-aptamer conjugate was significantly superior to that with unmodified aptamer. These results indicate that PMPC has potential as an aptamer or other nucleic acid drug modifier to replace or be compatible with PEG.
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element INTERFERON-GAMMA
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element METHACRYLATE
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element SHOCK
700 12 - ADDED ENTRY--PERSONAL NAME
Personal name Cho, S.
700 12 - ADDED ENTRY--PERSONAL NAME
Personal name Hori, M.
700 12 - ADDED ENTRY--PERSONAL NAME
Personal name Ueki, R.
700 12 - ADDED ENTRY--PERSONAL NAME
Personal name Saito, Y.
700 12 - ADDED ENTRY--PERSONAL NAME
Personal name Nagai, Y.
700 12 - ADDED ENTRY--PERSONAL NAME
Personal name Iki, H.
700 12 - ADDED ENTRY--PERSONAL NAME
Personal name Sando, S.
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://drive.google.com/file/d/1dvAb2oFWycoJq_ErbZBPYLsbuFVWWdML/view?usp=drive_link">https://drive.google.com/file/d/1dvAb2oFWycoJq_ErbZBPYLsbuFVWWdML/view?usp=drive_link</a>
Public note Para ver el documento ingresa a Google con tu cuenta: @cicy.edu.mx
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme Clasificación local
Koha item type Documentos solicitados
Holdings
Lost status Source of classification or shelving scheme Damaged status Not for loan Collection Home library Current library Shelving location Date acquired Total checkouts Full call number Date last seen Price effective from Koha item type
  Clasificación local     Ref1 CICY CICY Documento préstamo interbibliotecario 09.10.2025   B-21991 09.10.2025 09.10.2025 Documentos solicitados